Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 143763, 10 pages
http://dx.doi.org/10.1155/2014/143763
Review Article

Testosterone Deficiency, Cardiac Health, and Older Men

1Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK
2IDOP, University of Bedfordshire, Putteridge Bury Campus, Luton, Bedfordshire LU2 8LE, UK
3The Prostate Centre, 32 Wimpole Street, London W1G 8GT, UK
4The Luton & Dunstable Hospital, Lewsey Road, Luton, Bedfordshire LU4 0DZ, UK

Received 26 November 2013; Revised 12 January 2014; Accepted 5 February 2014; Published 10 April 2014

Academic Editor: Antonio Aversa

Copyright © 2014 G. Hackett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Wang, E. Nieschlag, R. S. Swerdloff et al., “Investigation, treatment, and monitoring of late-onset hypogonadism in Males, ISA, ISSAM, EAU, EAA, ASA recommendation,” European Urology, vol. 55, pp. 21–130, 2009. View at Google Scholar
  2. K. Wylie, M. Rees, G. Hackett et al., “Androgens, health and sexuality in women and men,” Maturitas, vol. 67, no. 3, pp. 275–289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. F. C. W. Wu, A. Tajar, J. M. Beynon et al., “Identification of late-onset hypogonadism in middle-aged and elderly men,” The New England Journal of Medicine, vol. 363, no. 2, pp. 123–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 6, pp. 1995–2010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K.-T. Khaw, M. Dowsett, E. Folkerd et al., “Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study,” Circulation, vol. 116, no. 23, pp. 2694–2701, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-Y. Oh, E. Barrett-Connor, N. M. Wedick, and D. L. Wingard, “Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study,” Diabetes Care, vol. 25, no. 1, pp. 55–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Shores, A. M. Matsumoto, K. L. Sloan, and D. R. Kivlahan, “Low serum testosterone and mortality in male veterans,” Archives of Internal Medicine, vol. 166, no. 15, pp. 1660–1665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. Å. Tivesten, L. Vandenput, F. Labrie et al., “Low serum testosterone and estradiol predict mortality in elderly men,” Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 7, pp. 2482–2488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Vikan, H. Schirmer, I. Njølstad, and J. Svartberg, “Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø study,” European Journal of Endocrinology, vol. 161, no. 3, pp. 435–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Corona, M. Monami, V. Boddi et al., “Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction,” Journal of Sexual Medicine, vol. 7, no. 4, pp. 1557–1564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Maggio, F. Lauretani, G. P. Ceda et al., “Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the chianti area (InCHIANTI) study,” Archives of Internal Medicine, vol. 167, no. 20, pp. 2249–2254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Hyde, P. E. Norman, L. Flicker et al., “Low free testosterone predicts mortality from cardiovascular disease but not other causes: the health in men study,” Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 1, pp. 179–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. B. B. Yeap, Z. Hyde, O. P. Almeida et al., “Lower testosterone levels predict incident stroke and transient ischemic attack in older men,” Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 7, pp. 2353–2359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. Araujo, J. M. Dixon, E. A. Suarez, M. H. Murad, L. T. Guey, and G. A. Wittert, “Endogenous testosterone and mortality in men: a systematic review and meta-analysis,” Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 10, pp. 3007–3019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Haring, H. V. Völzke, A. Steveling et al., “Association of low testosterone levels with all-cause mortality by different cut-offs from recent studies,” European Heart Journal, vol. 31, pp. 1494–1501, 2010. View at Google Scholar
  16. S. R. Pye, I. T. Huhtaniemi, J. D. Finn et al., “Late-onset hypogonadism and mortality in aging men,” The Journal of Clinical Endocrinology & Metabolism, 2013. View at Publisher · View at Google Scholar
  17. B. B. Yeap, H. Alfonso, S. A. P. Chubb et al., “In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 1, 2014. View at Publisher · View at Google Scholar
  18. M. Peyman, M. D. Oskui, W. J. French et al., “Testosterone and the cardiovascular system. A comprehensive review of the literature,” The American Heart Association Contempory Reviews, vol. 2, Article ID e000272, 2013. View at Publisher · View at Google Scholar
  19. L. Li, C. Y. Guo, E. Z. Jia et al., “Testosterone is negatively associated with the severity of coronary artery disease in men,” Asian Journal of Andrology, vol. 14, pp. 875–878, 2012. View at Google Scholar
  20. C. J. Malkin, P. J. Pugh, P. D. Morris, S. Asif, T. H. Jones, and K. S. Channer, “Low serum testosterone and increased mortality in men with coronary heart disease,” Heart, vol. 96, no. 22, pp. 1821–1825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Muraleedaran, H. Marsh, D. Kapoor, K. S. Channer, and T. H. Jones, “Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes,” European Journal of Endocrinology, vol. 169, no. 6, pp. 725–733, 2013. View at Google Scholar
  22. D. Kapoor, H. Aldred, S. Clark, K. S. Channer, and T. H. Jones, “Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity,” Diabetes Care, vol. 30, no. 4, pp. 911–917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. I. Hackett, N. S. Cole, A. A. Deshpande, M. D. Popple, D. Kennedy, and P. Wilkinson, “Biochemical hypogonadism in men with type 2 diabetes in primary care practice,” British Journal of Diabetes and Vascular Disease, vol. 9, no. 5, pp. 226–231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Saad, A. Aversa, A. M. Isidori, L. Zafalon, M. Zitzmann, and L. Gooren, “Onset of effects of testosterone treatment and time span until maximum effects are achieved,” European Journal of Endocrinology, vol. 165, no. 5, pp. 675–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Haffner, J. Shaten, M. P. Stern, G. D. Smith, and L. Kuller, “Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial,” The American Journal of Epidemiology, vol. 143, no. 9, pp. 889–897, 1996. View at Google Scholar · View at Scopus
  26. A. M. Traish, A. Haider, G. Doros, and F. Saad, “Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study,” International Journal of Clinical Practice, vol. 68, no. 3, pp. 314–329, 2014. View at Publisher · View at Google Scholar
  27. S. Y. Kalinchenko, Y. A. Tishova, G. J. Mskhalaya, L. J. G. Gooren, E. J. Giltay, and F. Saad, “Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study,” Clinical Endocrinology, vol. 73, no. 5, pp. 602–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. E. Heufelder, F. Saad, M. C. Bunck, and L. Gooren, “Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone,” Journal of Andrology, vol. 30, no. 6, pp. 726–733, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. K. M. English, O. Mandour, R. P. Steeds, M. J. Diver, T. H. Jones, and K. S. Channer, “Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms,” European Heart Journal, vol. 21, no. 11, pp. 890–894, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Caminiti, M. Volterrani, F. Iellamo et al., “Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomized study,” Journal of the American College of Cardiology, vol. 54, no. 10, pp. 919–927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Svartberg, D. von Mühlen, E. Mathiesen, O. Joakimsen, K. H. Bønaa, and E. Stensland-Bugge, “Low testosterone levels are associated with carotid atherosclerosis in men,” Journal of Internal Medicine, vol. 259, no. 6, pp. 576–582, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Basaria, A. D. Coviello, T. G. Travison et al., “Adverse events associated with testosterone administration,” The New England Journal of Medicine, vol. 363, no. 2, pp. 109–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Kapoor, H. Aldred, S. Clark, K. S. Channer, and T. H. Jones, “Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity,” Diabetes Care, vol. 30, no. 4, pp. 911–917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Dobrzycki, W. Serwatka, S. Nadlewski et al., “An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males,” The Journal of Medical Investigation, vol. 50, pp. 162–169, 2003. View at Google Scholar
  35. G. Rosano, I. Sheiban, R. Massaro et al., “Low testosterone levels are associated with coronary artery disease in male patients with angina,” International Journal of Impotence Research, vol. 19, pp. 176–182, 2007. View at Google Scholar
  36. L. Li, C. Y. Guo, E. Z. Jia et al., “Testosterone is negatively associated with the severity of coronary atherosclerosis in men,” Asian Journal of Andrology, vol. 14, pp. 875–878, 2012. View at Google Scholar
  37. G. B. Phillips, B. H. Pinkernell, and T. Y. Jing, “The association of hypotestosteronemia with coronary artery disease in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, pp. 701–706, 1994. View at Google Scholar
  38. G. Hackett, N. Cole, M. Bhartia et al., “The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study),” International Journal of Clinical Practice, vol. 68, no. 2, pp. 203–215, 2014. View at Google Scholar
  39. A. Mathur, C. Malkin, B. Saleem, R. Muthusammy, C. H. Jones, and K. Channer, “The long term benefits of testosterone on angina threshold and atheroma in men,” European Journal of Endocrinology, vol. 161, no. 3, pp. 443–449, 2009. View at Google Scholar
  40. K. M. English, R. P. Steeds, T. H. Jones, M. J. Diver, and K. S. Channer, “Low-dose transdermal testosterone therapy improves angina threshold in men with chromic stable angina: a randomized, double-blind, placebo-controlled study,” Circulation, vol. 102, no. 16, pp. 1906–1911, 2000. View at Google Scholar · View at Scopus
  41. C.-X. Bai, J. Kurokawa, M. Tamagawa, H. Nakaya, and T. Furukawa, “Nontranscriptional regulation of cardiac repolarization currents by testosterone,” Circulation, vol. 112, no. 12, pp. 1701–1710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Selvin, M. Feinleib, L. Zhang et al., “Androgens and diabetes in men: results from the third National Health and Nutrition Survey (NHANES-III),” Diabetes Care, vol. 30, pp. 234–238, 2007. View at Google Scholar
  43. R. K. Stellato, H. A. Feldman, O. Hamdy, E. S. Horton, and J. B. Mckinlay, “Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study,” Diabetes Care, vol. 23, no. 4, pp. 490–494, 2000. View at Google Scholar · View at Scopus
  44. M. Maggio, S. Basaria, A. Ble et al., “Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men,” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 1, pp. 345–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Migliaccio, D. Francomano, R. Bruzziches et al., “Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male,” International Journal of Endocrinology, vol. 2013, Article ID 182753, 6 pages, 2013. View at Publisher · View at Google Scholar
  46. J. Macleod, G. Davey Smith, C. Metcalfe, and C. Hart, “INTERHEART,” The Lancet, vol. 365, no. 9454, pp. 118–119, 2005. View at Google Scholar · View at Scopus
  47. C. Wang, R. S. Swerdloff, R. Iranmanesh et al., “Testosterone gel improves sexual function, mood, muscle strength and body composition in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 8, pp. 2839–2853, 2000. View at Google Scholar
  48. https://www.diabetes.org.uk/Documents/Reports/State-of-the-Nation-2012.pdf.
  49. T. H. Jones, “A placebo controlled study on the effects of transdermal testosterone gel in hypogonadal men with type ii diabetes or metabolic syndrome in diabetic control and insulin sensitivity: the TIMES 2 study,” Diabetes Care, vol. 34, pp. 828–837, 2011. View at Google Scholar
  50. D. Kapoor, E. Goodwin, K. S. Channer, and T. H. Jones, “Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes,” European Journal of Endocrinology, vol. 154, no. 6, pp. 899–906, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. M. I. Naharci, M. Pinar, E. Bolu, and A. Olgun, “Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism,” Endocrine Practice, vol. 13, no. 6, pp. 629–635, 2007. View at Google Scholar · View at Scopus
  52. M. A. Boyanov, Z. Boneva, and V. G. Christov, “Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency,” Aging Male, vol. 6, no. 1, pp. 1–7, 2003. View at Google Scholar · View at Scopus
  53. G. Hackett, N. Cole, M. Bhartia et al., “The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study),” International Journal of Clinical Practice, vol. 68, no. 2, pp. 203–215, 2014. View at Publisher · View at Google Scholar
  54. G. Hackett, N. Cole, M. Bhartia, P. Wilkinson, J. Raju, and P. Wilkinson, “Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study,” The Journal of Sexual Medicine, 2013. View at Publisher · View at Google Scholar
  55. M. Shores, N. L. Smith, C. W. Forsberg, and B. D. Anawalt, “Marsumoto AM Testosterone treatment and mortality in men with low testosterone,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, 2012. View at Publisher · View at Google Scholar
  56. L. Morganuv, I. Denisola, T. Rohzkova et al., “Androgen deficit and its treatment in stroke male patients with type II diabetes,” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 111, no. 8, part 2, pp. 21–24, 2011. View at Google Scholar
  57. R. Vigen, C. I. O’Donnell, A. E. Baron et al., “Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels,” The Journal of the American Medical Association, vol. 310, no. 17, pp. 1829–1836, 2013. View at Google Scholar
  58. A. Nehra, G. Jackson, M. Miner et al., “The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease,” Mayo Clinic Proceedings, vol. 8, pp. 766–778, 2013. View at Google Scholar
  59. A. R. Cappola, “Testosterone therapy and risk of cardiovascular disease in men,” The Journal of the American Medical Association, vol. 310, no. 17, pp. 1805–1806, 2013. View at Google Scholar
  60. L. Xu, G. Freeman, B. J. Cowling, and C. M. Schooling, “Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials,” BMC Medicine, vol. 11, article 108, 2013. View at Publisher · View at Google Scholar
  61. O. M. Calof, A. B. Singh, M. L. Lee et al., “Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials,” Journals of Gerontology A, vol. 60, no. 11, pp. 1451–1457, 2005. View at Google Scholar · View at Scopus
  62. J. K. Parsons, “Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors,” Current Bladder Dysfunction Reports, vol. 5, pp. 212–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. D. J. Yassin, Y. El Douaihy, A. A. Yassin, J. Kashanian, R. Shabsigh, and J. Hammerer, “Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study,” World Journal of Urology, 2013. View at Publisher · View at Google Scholar
  64. D. Francomano, A. Ilacqua, R. Bruzziches, A. Lenzi, and A. Aversa, “Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome,” Urology, vol. 83, no. 1, pp. 167–174, 2014. View at Publisher · View at Google Scholar
  65. I. Eardley, “Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting “non-responders” into ‘responders’,” European Urology, vol. 50, no. 1, pp. 31–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. L. S. Marks, N. A. Mazer, E. Mostaghel et al., “Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 19, pp. 2351–2361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. E. García-Cruz, M. Piqueras, M. J. Ribal et al., “Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia,” BJU International, vol. 110, no. 6, part B, pp. E199–E202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. N. L. Keating, A. J. O'Malley, S. J. Freedland, and M. R. Smith, “Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer,” Journal of the National Cancer Institute, vol. 102, no. 1, pp. 39–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Hackett, N. Cole, M. Bhartia, D. Kennedy, J. Raju, and P. Wilkinson, “Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes,” The Journal of Sexual Medicine, vol. 10, no. 6, pp. 1612–1617, 2013. View at Google Scholar
  70. A. M. Isidori, E. Giannetta, D. Gianfrilli et al., “Effects of testosterone on sexual function in men: results of a meta-analysis,” Clinical Endocrinology, vol. 63, no. 4, pp. 381–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Home, J. Mant, J. Diaz, and C. Turner, “Management of type 2 diabetes: updated NICE guidance,” British Medical Journal, vol. 336, no. 7656, pp. 1306–1308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Hackett, G. Jackson, M. Kirby, and K. Wylie, “Evidence based medicine inevitably increase testosterone prescribing,” British Medical Journal, vol. 345, Article ID e6167, 2012. View at Google Scholar